Heart Disease News and Research

Latest Heart Disease News and Research

Techulon signs license with Virginia Tech Intellectual Properties to market DNA delivery platform

Techulon Inc., a life sciences company based in the Virginia Tech Corporate Research Center, has signed an exclusive license with Virginia Tech Intellectual Properties Inc. to market a new, traceable DNA delivery platform created to deliver genetic medicine to cells while carrying a beacon so scientists can follow its progress.

22 Oct 2010

FDA announces new label for HIV antiviral drug Invirase

The U.S. Food and Drug Administration today announced that new safety information has been added to the label for the HIV antiviral drug Invirase (saquinavir), describing potentially life-threatening side effects on the heart when used with Norvir (ritonavir), another HIV antiviral medication.

22 Oct 2010

New review outlines Bionovo's platform of estrogen receptor modulators for menopausal conditions

Bionovo, Inc. today announced the publication of a review of results from studies discussing new classes of estrogen receptor modulating drugs with distinct mechanism for pharmacological effect. The review is published in the most recent edition of Current Opinion in Pharmacology.

22 Oct 2010

Injecting apoA-V protein may reduce high triglyceride levels: Research

Injecting a protein that helps break down triglycerides may someday help treat an inherited form of high triglycerides, according to a new study in Arteriosclerosis, Thrombosis, and Vascular Biology, an American Heart Association journal.

22 Oct 2010

Stanford Hospital opens Nuclear Medicine and Molecular Imaging Clinic

The Nuclear Medicine and Molecular Imaging Clinic opening this month at Stanford Hospital will help advance a new generation of diagnostic techniques for earlier detection and improved management of cancer, heart disease and neurological disorders.

22 Oct 2010

New guidelines feature various key updates for stroke or TIA survivors

Treating metabolic syndrome and undergoing carotid angioplasty may prevent recurrent stroke or transient ischemic attack, according to revised American Heart Association/American Stroke Association guidelines.

22 Oct 2010

NIH awards three new SBIR grants to Taiga

Taiga Biotechnologies, Inc. today announced that the company has received three new Small Business Innovation Research (SBIR) grants from the National Institutes of Health, totaling $1.7 million. This adds to the two previous grants awarded to Taiga for various applications of its proprietary technology platforms, for a total in NIH funding to date of over $2.1 million.

22 Oct 2010

Study: apoA-V may reduce high triglyceride levels, coronary artery disease

An exciting new study conducted by Children's Hospital Oakland Research Institute scientists identified that an injection of the protein apolipoprotein A-V may reduce high triglyceride levels in the blood and subsequently reduce coronary artery disease. Like cholesterol, elevated levels of triglyceride, a fat in the blood, is associated with the increased risk of heart disease—the number one cause of death in the United States.

22 Oct 2010

Biomarkers can improve ability to identify patients at high risk of CKD: Study

Measuring three biomarkers in a single blood sample may improve physicians' ability to identify patients at high risk of developing chronic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

22 Oct 2010

Regulus present advancements in microRNA platform at Oligonucleotide Therapeutics Society meeting

Regulus Therapeutics Inc. announced today that advancements from its leading microRNA platform and product pipeline were presented at the "6th Annual Meeting of the Oligonucleotide Therapeutics Society" held October 20 - 23, 2010 in Dana Point, California.

22 Oct 2010

Atherotech to present VAP Cholesterol Test at OMED 2010

Atherotech Diagnostics Lab will showcase its VAP Cholesterol Test in booth 324 at the American Osteopathic Association's 115th Annual Osteopathic Medical Conference & Exposition (OMED 2010). The gathering of DOs, residents, interns, students, researchers and health care professionals will be held October 24-28 at Moscone Convention Center in San Francisco.

22 Oct 2010

Pinch of salt: How much is enough?

Salt restriction in the normal diet has come under debate. While scientists are questioning the complex role of sodium in the body and the need for salt restriction, surveys have found that dietary sodium has not gone down well in large populations despite awareness on the risks of too much salt intake.

21 Oct 2010

Potential SIDS cause found

A baffling condition Sudden Infant Death Syndrome (SIDS) that leads to the unexplained deaths of many infants worldwide may have been explained in new Australian research. The researchers monitored babies as they slept on their bellies and found that they have reduced blood pressure and an increased heart rates, compared with when they slept on their backs as recommended. This effect is seen more in babies aged two to three months, the age when babies are most at risk of SIDS.

21 Oct 2010

Australian stem cell line offers fresh approach to diabetes cure

Australian researchers have developed the country’s first diabetes specific stem cell line, a major advance for patients suffering from the chronic disease.

21 Oct 2010

Astellas suspends enrollment in ACT 5 study of KYNAPID in atrial fibrillation patients

Cardiome Pharma Corp. today announced that its co-development partner, Astellas Pharma US., Inc., has suspended patient enrollment in the ACT 5 study of KYNAPIDTM (vernakalant hydrochloride) Injection following a single unexpected serious adverse event of cardiogenic shock experienced by a patient with atrial fibrillation who received KYNAPID.

21 Oct 2010

Bruker installs BioSpec 170/25 system at CEA NeuroSpin research center

Bruker announced today that it has successfully installed its BioSpec® 170/25 system at the CEA NeuroSpin research center near Paris, France. The world's first horizontal ultra-high magnetic field 17.2 Tesla MRI system features a magnet bore diameter of 25 cm. It is equipped with a novel Bruker BGA-S™ gradient system with unsurpassed amplitude and slew rate specifications for cutting-edge preclinical in vivo imaging on small animals.

21 Oct 2010

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.

21 Oct 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010

Kensey Nash 2011 first quarter decreases 14% to $17.0 million

Kensey Nash Corporation , a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its first quarter ended September 30, 2010.

21 Oct 2010

Baxter third quarter net income increases 12% to $595 million

Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.

From Baxter International Inc. 21 Oct 2010